| 发明名称 | Vaccine for cervical cancer | ||
| 摘要 | The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer. | ||
| 申请公布号 | US9566323(B2) | 申请公布日期 | 2017.02.14 |
| 申请号 | US200913379212 | 申请日期 | 2009.10.20 |
| 申请人 | Eyegene Inc. | 发明人 | Kim Hong-Jin;Lee Na Gyong;Cho Yang-Je;Jang Jin-Wook;Kim Hyoung Jin;Kim Kwang Sung |
| 分类号 | A61K39/12;A61K39/39;A61K39/00 | 主分类号 | A61K39/12 |
| 代理机构 | Clark & Elbing LLP | 代理人 | Clark & Elbing LLP ;Michaud Susan M. |
| 主权项 | 1. A method for preventing human cervical cancer, comprising administering to a human a pharmaceutical composition comprising (a) (i) an L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, an L1 VLP of HPV type 18, or a combination thereof; and (ii) CIA05 as a deacylated non-toxic lipooligosaccharide (LOS), which is detoxificated by deacylation of lipid A of lipopolysaccharide isolated from E. coli (Escherichia coli); (b) a pharmaceutically acceptable carrier; and (c) aluminum hydroxide, with the proviso that the composition does not include bacterial DNA as an adjuvant. | ||
| 地址 | Seoul KR | ||